Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

IPS-7 (Adult Hodgkin Lymphoma)

The International Prognostic Score (IPS-7) remains a fundamental tool for baseline risk.

Evidence-based context for fast calculator use

Purpose:
International Prognostic Score (IPS-7) for advanced Hodgkin lymphoma — 7-factor risk stratification to guide ABVD vs intensified regimens.
Population:
patients with the specific hematologic diagnosis and disease phase described by the model
Factors:
Age ≥ 45 years?, Sex: Male?, Stage IV?, Albumin < 4.0 g/dL?, Hemoglobin < 10.5 g/dL?, WBC ≥ 15,000/mm³?, Lymphopenia?
Reference:
Hasenclever D, et al. N Engl J Med. 1998;339(21):1506-1514.
HomeIPS-7 (Adult Hodgkin Lymphoma)
Pin your most used calculators here by clicking the star in the dropdown.

IPS-7 (Adult Hodgkin Lymphoma)

Clinical Context & Background

The International Prognostic Score (IPS-7) remains a fundamental tool for baseline risk. In 2026, clinicians use this score to decide between ABVD and intensified regimens like BrECADD or N-AVD.
Primary Source EvidenceHasenclever D, et al. N Engl J Med. 1998;339(21):1506-1514.
Formula Logic
Sum of 7 independent risk factors

Reference Data

ScoreRisk GroupModern 5-Year PFS (Est.)
0-1Low Risk92-96%
2-3Intermediate Risk85-91%
≥ 4High Risk75-84%

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use IPS-7 (Adult Hodgkin Lymphoma) when international Prognostic Score (IPS-7) for advanced Hodgkin lymphoma — 7-factor risk stratification to guide ABVD vs intensified regimens.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning 0-1 through ≥ 4.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm morphology, molecular/cytogenetic data, treatment timing, laboratory units, and the current disease-specific guideline before acting.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Hematology scores are diagnosis-, phase-, and treatment-specific and should not be transferred between diseases.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients with the specific hematologic diagnosis and disease phase described by the model

How to apply this result

For a representative case, verify Age ≥ 45 years?, Sex: Male?, Stage IV?, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Hematology hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

NCCN-IPI (Lymphoma)CLL-IPIMIPI (Mantle Cell Lymphoma)

Frequently Asked Questions

When should IPS-7 (Adult Hodgkin Lymphoma) be used?

Use it for patients with the specific hematologic diagnosis and disease phase described by the model when all required inputs and the intended clinical setting are confirmed.

Can IPS-7 (Adult Hodgkin Lymphoma) determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.